ClinicalTrials.gg

Program

Alveltamig

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 16, 202511 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Zelgen Biopharmaceuticals1010 open or runningphase 3since Sep 16, 2025Jul 28, 2023Dec 2026phase 1 · NCT06592638
Hansoh Pharmaceutical Group11 open or runningphase 1since Aug 13, 2026Aug 13, 2026Sep 15, 2028phase 1 · NCT07892625

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2023First study: phase 2 study in Small Cell Lung CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT05978284 · 54 planned · China
  2. Feb 21, 2024Phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06283719 · 265 planned · China
  3. May 28, 2024Phase 2 study in Carcinoma, NeuroendocrineSuzhou Zelgen Biopharmaceuticals · NCT06440057 · 78 planned · China
  4. Sep 9, 2024Phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06592638 · 30 planned · United States
  5. Jun 9, 20252 phase 2 studiesSuzhou Zelgen Biopharmaceuticals · NCT07024277, NCT07038096
  6. Sep 16, 2025Phase 3 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07189455 · 420 planned · China
  7. Nov 13, 2025Phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07231445 · 100 planned · China
  8. Nov 20, 2025Phase 2 study in Solid TumorSuzhou Zelgen Biopharmaceuticals · NCT07258121 · 400 planned · China
  9. May 13, 2026Phase 3 study in Carcinoma, NeuroendocrineSuzhou Zelgen Biopharmaceuticals · NCT07595913 · 240 planned · China
  10. Aug 13, 2026Hansoh Pharmaceutical Group's first study: phase 1 study in Small Cell Lung CarcinomaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07892625 · 338 planned
  11. Oct 19, 2026Primary completion moved from 2026-04 to 2027-04Date moved laterphase 2 · +12 months · NCT06283719

Ahead

  1. Dec 2026Primary completion: phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06592638
  2. Apr 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06283719
  3. Sep 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07038096
  4. Dec 2027Primary completion: phase 2 study in Neuroendocrine Prostate CancerSuzhou Zelgen Biopharmaceuticals · NCT07024277

TargetBeta

CD3E →DLL3 →read by rule
“A trispecific T-cell engaging (TCE) antibody directed against two different epitopes of the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
obrixtamigBoehringer Ingelheimphase 311
gocatamigMerckphase 34
SHR-7787Jiangsu HengRui Medicinephase 21
clesitamigHoffmann-La Rochephase 12
HLX3901Fosun Pharmaphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07892625Small Cell Lung Carcinoma1Not yet recruitingHansoh Pharmaceutical GroupSep 15, 2028338
NCT07595913Carcinoma, Neuroendocrine · China3Not yet recruitingSuzhou Zelgen BiopharmaceuticalsJun 2028240
NCT07258121Solid Tumor · China2RecruitingSuzhou Zelgen BiopharmaceuticalsDec 2028400
NCT07231445Small Cell Lung Carcinoma · China1RecruitingSuzhou Zelgen BiopharmaceuticalsDec 2028100
NCT07189455Small Cell Lung Carcinoma · China3RecruitingSuzhou Zelgen BiopharmaceuticalsOct 2028420
NCT07038096Small Cell Lung Carcinoma · China2RecruitingSuzhou Zelgen BiopharmaceuticalsSep 2027350
NCT07024277Neuroendocrine Prostate Cancer · China2Not yet recruitingSuzhou Zelgen BiopharmaceuticalsDec 202760
NCT06592638Small Cell Lung Carcinoma · United States1RecruitingSuzhou Zelgen BiopharmaceuticalsDec 202630
NCT06440057Carcinoma, Neuroendocrine · China2RecruitingSuzhou Zelgen BiopharmaceuticalsMay 202678
NCT06283719Small Cell Lung Carcinoma · China2RecruitingSuzhou Zelgen BiopharmaceuticalsApr 2027265
NCT05978284Small Cell Lung Carcinoma · China2RecruitingSuzhou Zelgen BiopharmaceuticalsSep 202654

How it is read

Names in the registry

  • “ZG006”, 11 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.